PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.
November 25, 2024 at 2:20 PM
PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.
NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC
oncodaily.com/insight/201195
#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction
oncodaily.com/insight/201195
#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction
NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC - OncoDaily
NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC / cancer, darolutamide, docetaxel, Metastatic Hormone-sensitive Prostate Cancer,
oncodaily.com
December 11, 2024 at 5:07 PM
NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC
oncodaily.com/insight/201195
#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction
oncodaily.com/insight/201195
#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction
KEYNOTE-991 Trial Results: Pembrolizumab Plus Enzalutamide and ADT in mHSPC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-991 #IO #ADT #Pembrolizumab #Enzalutamide #mHSPC #ProstateCancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-991 #IO #ADT #Pembrolizumab #Enzalutamide #mHSPC #ProstateCancer
KEYNOTE-991. Pembrolizumab Fails to Improve OS in mHSPC
KEYNOTE-991 trial shows no survival benefit from adding pembrolizumab to enzalutamide and ADT in mHSPC.
oncodaily.com
May 24, 2025 at 9:29 PM
KEYNOTE-991 Trial Results: Pembrolizumab Plus Enzalutamide and ADT in mHSPC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-991 #IO #ADT #Pembrolizumab #Enzalutamide #mHSPC #ProstateCancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-991 #IO #ADT #Pembrolizumab #Enzalutamide #mHSPC #ProstateCancer
Presenting my work on real-world outcomes for patients with mHSPC treated with enzalutamide at #BOPA2026 this year.
If you've ever had doubts about the effect on outcomes of dose reducing, hopefully this will help to reassure! Patients on dose reductions did at least as well as those without.
If you've ever had doubts about the effect on outcomes of dose reducing, hopefully this will help to reassure! Patients on dose reductions did at least as well as those without.
October 2, 2026 at 3:43 PM
Presenting my work on real-world outcomes for patients with mHSPC treated with enzalutamide at #BOPA2026 this year.
If you've ever had doubts about the effect on outcomes of dose reducing, hopefully this will help to reassure! Patients on dose reductions did at least as well as those without.
If you've ever had doubts about the effect on outcomes of dose reducing, hopefully this will help to reassure! Patients on dose reductions did at least as well as those without.
Just in @bjuijournal.bsky.social: Our #TITAN post hoc analysis: Patients with ultralow 0.2 #PSA derived greatest benefit. Less pronounced addtl. benefit for .02
#mHSPC #ProstateCancer
👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social
#mHSPC #ProstateCancer
👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social
Post hoc analysis of TITAN examined the association between achieving ultralow prostate-specific antigen (PSA) levels (≤0.2 ng/mL) and clinical outcomes in patients with metastatic castration-sensitive #ProstateCancer (mCSPC) treated with apalutamide.
https://buff.ly/3CJA5bO
https://buff.ly/3CJA5bO
November 20, 2024 at 8:48 AM
Just in @bjuijournal.bsky.social: Our #TITAN post hoc analysis: Patients with ultralow 0.2 #PSA derived greatest benefit. Less pronounced addtl. benefit for .02
#mHSPC #ProstateCancer
👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social
#mHSPC #ProstateCancer
👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social
New Paper Alert: STAMPEDE Trial Results on Metformin in Metastatic Prostate Cancer Treatment
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #STAMPEDE #ProstateCancer #mPC #Metformin #mHSPC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #STAMPEDE #ProstateCancer #mPC #Metformin #mHSPC
STAMPEDE Trial: Metformin in Metastatic Prostate Cancer
STAMPEDE trial findings on the addition of metformin to standard treatment in mHSPC. Learn about survival and metabolic outcomes.
oncodaily.com
July 9, 2025 at 8:37 PM
New Paper Alert: STAMPEDE Trial Results on Metformin in Metastatic Prostate Cancer Treatment
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #STAMPEDE #ProstateCancer #mPC #Metformin #mHSPC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #STAMPEDE #ProstateCancer #mPC #Metformin #mHSPC
Declan Murphy discusses fast track queues at the Pearly Gates and doublet vs triplet therpy for mHSPC! Teaser for current GU Cast PROSPECT Part 2 #urology #podcast #prostatecancer
November 23, 2024 at 6:44 AM
Declan Murphy discusses fast track queues at the Pearly Gates and doublet vs triplet therpy for mHSPC! Teaser for current GU Cast PROSPECT Part 2 #urology #podcast #prostatecancer
Prostate Cancer Therapy Cardiotoxicity Map:
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
December 16, 2024 at 9:28 PM
Prostate Cancer Therapy Cardiotoxicity Map:
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ!
www.onclive.com/view/capivas...
www.onclive.com/view/capivas...
Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC
Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.
www.onclive.com
November 26, 2024 at 5:45 PM
Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ!
www.onclive.com/view/capivas...
www.onclive.com/view/capivas...
Important data @ccparker.bsky.social what are your thoughts on the duration of ADT and Abi in low volume mHSPC? Data free zone but lifelong ADT may need to be rethought?
November 25, 2024 at 3:17 PM
Important data @ccparker.bsky.social what are your thoughts on the duration of ADT and Abi in low volume mHSPC? Data free zone but lifelong ADT may need to be rethought?
I am reposting to highlight 2 other terms we hope we can gain consensus around: ARPI (rather than ARSI, NHT etc) and Combination therapy for mHSPC (instead of doublet/triplet or treatment intensification). Please read the rationale in this short editorial. @yalecancer.bsky.social
Words matter in medicine: for accuracy among clinicians + researchers, and for patients, to understand their disease. We propose avoiding “castration” by unifying around HSPC and coin a new phrase ARPC for “androgen deprivation resistant prostate cancer” www.sciencedirect.com/science/arti...
What’s in a Name? Why Words Matter in Advanced Prostate Cancer
www.sciencedirect.com
January 10, 2025 at 1:10 PM
I am reposting to highlight 2 other terms we hope we can gain consensus around: ARPI (rather than ARSI, NHT etc) and Combination therapy for mHSPC (instead of doublet/triplet or treatment intensification). Please read the rationale in this short editorial. @yalecancer.bsky.social
AOTMiT recommends against Akeega reimbursement in metastatic prostate cancer, citing comparator uncertainty. https://www.mattheneus.com/editorial/aotmit-akeega-mhspc-negative-reimbursement-amplitude-comparator-uncertainty-2026-09-29 #HTA #HealthEconomics
October 4, 2026 at 9:04 AM
AOTMiT recommends against Akeega reimbursement in metastatic prostate cancer, citing comparator uncertainty. https://www.mattheneus.com/editorial/aotmit-akeega-mhspc-negative-reimbursement-amplitude-comparator-uncertainty-2026-09-29 #HTA #HealthEconomics
Oh and I was a GU research nurse at a major university cancer center. There is so many cutting edge treatments. My first patient with mHSPC on one of my first studies in 2016 is still alive.
May 18, 2025 at 11:22 PM
Oh and I was a GU research nurse at a major university cancer center. There is so many cutting edge treatments. My first patient with mHSPC on one of my first studies in 2016 is still alive.
Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
In this Review, Alice Bernard-Tessier & @mishabeltran.bsky.social discuss the underlying biology in mHSPC and highlight current knowledge gaps: doi.org/10.1172/JCI2...
In this Review, Alice Bernard-Tessier & @mishabeltran.bsky.social discuss the underlying biology in mHSPC and highlight current knowledge gaps: doi.org/10.1172/JCI2...
February 3, 2026 at 5:15 PM
Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
In this Review, Alice Bernard-Tessier & @mishabeltran.bsky.social discuss the underlying biology in mHSPC and highlight current knowledge gaps: doi.org/10.1172/JCI2...
In this Review, Alice Bernard-Tessier & @mishabeltran.bsky.social discuss the underlying biology in mHSPC and highlight current knowledge gaps: doi.org/10.1172/JCI2...
Love to see an implementation win in @ascocancer.bsky.social/ #JCOOP ⬇️
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
November 4, 2025 at 3:52 AM
Love to see an implementation win in @ascocancer.bsky.social/ #JCOOP ⬇️
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer - Rana McKay
https://oncodaily.com/blog/rana-mckay194507
ucsdmedschool.bsky.social theaacr.bsky.social
##Abiraterone ##Cancer ##CAPItello281 ##Capivasertib ##Medicine ##Health ##MedOnc ##mHSPC ##OncoDaily ##Oncology ##PTEN
https://oncodaily.com/blog/rana-mckay194507
ucsdmedschool.bsky.social theaacr.bsky.social
##Abiraterone ##Cancer ##CAPItello281 ##Capivasertib ##Medicine ##Health ##MedOnc ##mHSPC ##OncoDaily ##Oncology ##PTEN
Rana McKay: CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer - OncoDaily
Rana McKay: CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer / abiraterone, cancer, CAPItello-281, Capivasertib, fight
oncodaily.com
December 3, 2024 at 5:00 AM
CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer - Rana McKay
https://oncodaily.com/blog/rana-mckay194507
ucsdmedschool.bsky.social theaacr.bsky.social
##Abiraterone ##Cancer ##CAPItello281 ##Capivasertib ##Medicine ##Health ##MedOnc ##mHSPC ##OncoDaily ##Oncology ##PTEN
https://oncodaily.com/blog/rana-mckay194507
ucsdmedschool.bsky.social theaacr.bsky.social
##Abiraterone ##Cancer ##CAPItello281 ##Capivasertib ##Medicine ##Health ##MedOnc ##mHSPC ##OncoDaily ##Oncology ##PTEN
I was interviewed recently about my prostate cancer journey. It was difficult, but it felt really good talking about it! Please read it! Here is the link. Thank you! prostatecancer.net/insider-pete...
Living Actively with Metastatic Hormone-Sensitive Prostate Cancer
Prostate cancer doesn't have to slow you down. Discover empowering strategies, practical advice, and inspiring stories for continuing your everyday activities and living fully with mHSPC.
prostatecancer.net
July 1, 2025 at 10:05 PM
I was interviewed recently about my prostate cancer journey. It was difficult, but it felt really good talking about it! Please read it! Here is the link. Thank you! prostatecancer.net/insider-pete...
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations.
Read the opinion by @ecastromarcos.bsky.social in the #ESMODailyReporter
🔗 buff.ly/b4cgGKB
#ProstateCancer #mHSPC #PersonalisedMedicine
Read the opinion by @ecastromarcos.bsky.social in the #ESMODailyReporter
🔗 buff.ly/b4cgGKB
#ProstateCancer #mHSPC #PersonalisedMedicine
June 26, 2025 at 7:30 AM
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations.
Read the opinion by @ecastromarcos.bsky.social in the #ESMODailyReporter
🔗 buff.ly/b4cgGKB
#ProstateCancer #mHSPC #PersonalisedMedicine
Read the opinion by @ecastromarcos.bsky.social in the #ESMODailyReporter
🔗 buff.ly/b4cgGKB
#ProstateCancer #mHSPC #PersonalisedMedicine
Dr. Daniel George takes the stage to review abstract 14: PROs & tolerability of capi + abi vs placebo + abi in pts w PTEN-deficient mHSPC #GU26
February 26, 2026 at 7:19 PM
Dr. Daniel George takes the stage to review abstract 14: PROs & tolerability of capi + abi vs placebo + abi in pts w PTEN-deficient mHSPC #GU26
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.
annalsofoncology.org
May 20, 2025 at 6:16 PM
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
💊 Novartis’ Pluvicto Hits Key Trial Goal, Eyes Expansion to Earlier Prostate Cancer Use Novartis' radioligand therapy Pluvicto has met its primary endpoint in a Phase III trial for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), showing a statistically
June 2, 2025 at 5:22 AM
💊 Novartis’ Pluvicto Hits Key Trial Goal, Eyes Expansion to Earlier Prostate Cancer Use Novartis' radioligand therapy Pluvicto has met its primary endpoint in a Phase III trial for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), showing a statistically
Evaluating time to metastasis and survival in patients with metachronous mHSPC receiving ADT intensification post-prostatectomy. 📊 A real-world study offering valuable insights into treatment outcomes @ascocancer.bsky.social #GU25
February 13, 2025 at 8:08 PM
Evaluating time to metastasis and survival in patients with metachronous mHSPC receiving ADT intensification post-prostatectomy. 📊 A real-world study offering valuable insights into treatment outcomes @ascocancer.bsky.social #GU25
Exploring real-world treatment patterns and survival in men with mCRPC who progressed from mHSPC between 2020-2023 in the US. Key insights on treatment outcomes and patient journeys. @ascocancer.bsky.social #GU25
February 13, 2025 at 8:08 PM
Exploring real-world treatment patterns and survival in men with mCRPC who progressed from mHSPC between 2020-2023 in the US. Key insights on treatment outcomes and patient journeys. @ascocancer.bsky.social #GU25
Gerhardt Attard shares how molecular transcriptome-based tests may help identify mHSPC patients who benefit most from treatment - moving toward more personalised care👨
#ProstateCancer #Oncology #OncSky #MedEd #MedSky
#ProstateCancer #Oncology #OncSky #MedEd #MedSky
October 18, 2025 at 9:20 AM
Gerhardt Attard shares how molecular transcriptome-based tests may help identify mHSPC patients who benefit most from treatment - moving toward more personalised care👨
#ProstateCancer #Oncology #OncSky #MedEd #MedSky
#ProstateCancer #Oncology #OncSky #MedEd #MedSky
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC #ONS25 #pcsm #oncology www.onclive.com/view/darolut...
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC
ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.
www.onclive.com
April 10, 2025 at 7:33 PM
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC #ONS25 #pcsm #oncology www.onclive.com/view/darolut...